Mizuho Maintains Neutral on Cerevel Therapeutics Hldg, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Graig Suvannavejh maintains a Neutral rating on Cerevel Therapeutics Hldg (NASDAQ:CERE) and raises the price target from $25 to $45.

February 16, 2024 | 11:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mizuho analyst Graig Suvannavejh maintains a Neutral rating on Cerevel Therapeutics Hldg but raises the price target from $25 to $45.
The increase in price target from $25 to $45 by Mizuho reflects a positive outlook on Cerevel Therapeutics Hldg's future performance, potentially leading to increased investor interest and a positive short-term impact on the stock price. The Neutral rating suggests that while the analyst sees improved prospects, there may still be factors that could limit the stock's upward movement in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100